CEBPZ and acute myeloid leukemia: NK-AML was associated with intermediate risk with a 5-year EFS of 48% (95% CI: 41–54%), inferior to CBF-AML (62%; CI: 56–68%), but superior compared to KMT2A rearranged AML (38%; CI: 31–46%) and other AK-AML (38%; CI: 32–44%) (Figure 4A).